Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
54
SNYNF Quote, Financials, Valuation and Earnings
Last price:
$95.89
Seasonality move
:
1.43%
Day range:
$95.89 - $97.25
52-week range:
$91.81 - $122.03
Dividend yield:
4.59%
P/E ratio:
17.10x
P/S ratio:
2.46x
P/B ratio:
1.46x
Volume:
733
Avg. volume:
40.9K
1-year change:
-5.99%
Market cap:
$117.2B
Revenue:
$47.9B
EPS (TTM):
$5.61
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sanofi SA has 33.68% upside to fair value with a price target of -- per share.
SNYNF vs. S&P 500
-
Over the past 5 trading days, Sanofi SA has underperformed the S&P 500 by -0.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sanofi SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sanofi SA has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Sanofi SA reported revenues of $11.2B.
Earnings Growth
-
Sanofi SA has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sanofi SA reported earnings per share of $1.60.
Enterprise value:
129.7B
EV / Invested capital:
--
Price / LTM sales:
2.46x
EV / EBIT:
14.58x
EV / Revenue:
2.67x
PEG ratio (5yr expected):
0.41x
EV / Free cash flow:
17.02x
Price / Operating cash flow:
15.70x
Enterprise value / EBITDA:
12.14x
Gross Profit (TTM):
$34.5B
Return On Assets:
4.85%
Net Income Margin (TTM):
13.98%
Return On Equity:
8.47%
Return On Invested Capital:
6.79%
Operating Margin:
23.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $43.1B | $44B | $48.6B | $10.6B | $11.2B | |
| Gross Profit | $30.5B | $30.4B | $34.5B | $7.3B | $8.1B | |
| Operating Income | $11.6B | $9B | $10.8B | $2.1B | $2.6B | |
| EBITDA | $12.9B | $8.3B | $10.7B | $2B | $2.9B | |
| Diluted EPS | $5.58 | $3.95 | $5.61 | $0.99 | $1.60 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $47.6B | |
| Total Assets | -- | -- | -- | -- | $142.8B | |
| Current Liabilities | -- | -- | -- | -- | $34.9B | |
| Total Liabilities | -- | -- | -- | -- | $62.2B | |
| Total Equity | -- | -- | -- | -- | $80.5B | |
| Total Debt | -- | -- | -- | -- | $20.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $95.6M | $2.2B | |
| Cash From Investing | -- | -- | -- | -$404.1M | -$816.5M | |
| Cash From Financing | -- | -- | -- | $825.5M | -$622.9M | |
| Free Cash Flow | -- | $10.5B | $7.6B | $95.6M | $2.2B | |
SNYNF
Sector
Market Cap
$117.2B
$34.5M
Price % of 52-Week High
78.58%
49.05%
Dividend Yield
4.59%
0%
Shareholder Yield
10.63%
-1.01%
1-Year Price Total Return
-5.99%
-35.15%
Beta (5-Year)
0.297
0.615
Dividend yield:
4.59%
Annualized payout:
$4.05
Payout ratio:
74.53%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$97.04
200-day SMA
Sell
Level
$103.69
Bollinger Bands (100)
Sell
Level
97.66 - 112.18
Chaikin Money Flow
Buy
Level
1.1K
20-day SMA
Sell
Level
$96.69
Relative Strength Index (RSI14)
Sell
Level
44.58
ADX Line
Sell
Level
14.93
Williams %R
Neutral
Level
-69.505
50-day SMA
Sell
Level
$100.07
MACD (12, 26)
Buy
Level
23.93
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-365
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.3195)
Buy
Beneish M-Score
(Annual)
Level (-2.7687)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-2.4295)
Buy
Piotroski F Score
(Annual)
Level (9)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Stock Forecast FAQ
In the current month, SNYNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNYNF average analyst price target in the past 3 months is --.
-
Where Will Sanofi SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sanofi SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sanofi SA?
Analysts are divided on their view about Sanofi SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sanofi SA is a Sell and believe this share price will drop from its current level to --.
-
What Is Sanofi SA's Price Target?
The price target for Sanofi SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNYNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sanofi SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SNYNF?
You can purchase shares of Sanofi SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sanofi SA shares.
-
What Is The Sanofi SA Share Price Today?
Sanofi SA was last trading at $95.89 per share. This represents the most recent stock quote for Sanofi SA. Yesterday, Sanofi SA closed at $95.89 per share.
-
How To Buy Sanofi SA Stock Online?
In order to purchase Sanofi SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 21.96% over the past day.
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 14.38% over the past day.
